Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.36 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1424963 | 0.87 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1LMNASMN1; SMN2KDM4E | |
| SCHEMBL3401912 | 0.85 | ALDH1A1 (0.56) | ALDH1A1L3MBTL1PDE2ALMNASMN1; SMN2 | |
| SCHEMBL8962911 | 0.83 | ALDH1A1 (0.48) | ALDH1A1L3MBTL1LMNASMN1; SMN2KDM4E | |
| SCHEMBL29452983 | 0.82 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1PDE2ALMNASMN1; SMN2 | |
| SCHEMBL8773240 | 0.81 | L3MBTL1 (0.49) | ALDH1A1L3MBTL1LMNASMN1; SMN2KDM4E | |
| SCHEMBL7241847 | 0.81 | ALDH1A1 (0.46) | ALDH1A1L3MBTL1SMN1; SMN2KDM4ERAB9A | |
| SCHEMBL21815761 | 0.80 | SIRT6 (0.38) | ALDH1A1KDM4ERAB9AMEN1KMT2A | |
| SCHEMBL12336074 | 0.79 | ALDH1A1 (0.43) | ALDH1A1L3MBTL1LMNAKDM4ERAB9A | |
| SCHEMBL27769272 | 0.79 | L3MBTL1 (0.44) | ALDH1A1L3MBTL1PDE2ALMNASMN1; SMN2 | |
| SCHEMBL2088106 | 0.77 | NOS3 (0.45) | ALDH1A1L3MBTL1SMN1; SMN2KDM4ERAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098060-A1 | MACROCYCLIC CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2026-04-09 | — | — | US | disclosed |
| EP-4587443-A1 | MACROCYCLIC CFTR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2025-07-23 | — | — | EP | disclosed |
| CN-120058708-A | Alkynyl alcohol derivative and medical application thereof | 中国药科大学 | 2025-05-30 | — | — | CN | disclosed |
| WO-2024056798-A1 | MACROCYCLIC CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-03-21 | — | — | WO | disclosed |
| US-20230203019-A1 | Piperazine Cyclic Ureas | SIRONAX (BEIJING) CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203019-A1 | Piperazine Cyclic Ureas | SIRONAX (BEIJING) CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| CN-106083738-A | A kind of method utilizing phase transfer catalyst to prepare herbicide bispyribac-sodium | 淄博新农基农药化工有限公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-1136217-C | 4-aryloxindoles as inhibitor of JNK protein kinases | - | 2004-01-28 | — | — | CN | disclosed |
| CN-1330648-A | 4-aryloxindoles as inhibitor of JNK protein kinases | HOFFMANN LA ROCKE AG F (CH) | 2002-01-09 | — | — | CN | disclosed |
| EP-1149093-A1 | 4-ARYLOXINDOLES AS INHIBITORS OF JNK PROTEIN KINASES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-10-31 | — | — | EP | disclosed |
| US-6307056-B1 | INHIBIT OR MODULATE PROTEIN KINASES, IN PARTICULAR JNK PROTEIN KINASES. | HOFFMAN-LA ROCHE INC. | 2001-10-23 | — | — | US | disclosed |
| WO-2000035909-A1 | 4-ARYLOXINDOLES AS INHIBITORS OF JNK PROTEIN KINASES | F. HOFFMANN-LA ROCHE AG (CH) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098060-A1 | MACROCYCLIC CFTR MODULATORS | CFTR, CLIC1, ARRB1 | ALDH1A1 1794/4885L3MBTL1 4158/4885PDE2A 726/4885 |
| US-20230203019-A1 | Piperazine Cyclic Ureas | RIPK1, RIPK3, RIPK4 | ALDH1A1 3602/4885L3MBTL1 4087/4885PDE2A 1578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.